Latest Biotech News

Function Health raised a $298 million Series B led by Redpoint Ventures, valuing the lab‑testing subscription startup at approximately $2.5 billion. The company offers consumers direct access to...

Bayer won accelerated FDA approval for Hyrnuo (sevabertinib) in adults with advanced HER2‑mutant non‑small‑cell lung cancer after prior systemic therapy. The decision positions Hyrnuo to compete...

Nurix Therapeutics announced a targeted workforce reduction while initiating a pivotal Phase 2 (DAYBreak) trial of bexobrutideg, an oral BTK degrader aimed at relapsed or refractory chronic...

Multiple health organizations and scientific outlets flagged a revision to the CDC’s vaccine safety web content that introduced language suggesting uncertainty about whether vaccines can cause...

Abbott announced a definitive agreement to acquire Exact Sciences, the maker of Cologuard and Oncotype DX, in a transaction that values Exact at roughly $21 billion in cash and about $23 billion...

The FDA granted approval to Bayer’s oral HER2‑directed drug Hyrnuo for adults with locally advanced or metastatic HER2‑mutant non‑small cell lung cancer, clearing a new targeted option for...

Contineum Therapeutics reported that PIPE‑307, an oral M1 receptor antagonist developed with Janssen, failed to meet its primary efficacy endpoint in a Phase 2 VISTA trial in relapsing‑remitting...

Nurix Therapeutics announced a targeted workforce reduction while initiating the DAYBreak pivotal Phase 2 trial of its oral BTK degrader bexobrutideg in relapsed or refractory chronic lymphocytic...

Ensoma disclosed a roughly 50% reduction in headcount as it transitions from platform development toward clinical execution, focusing resources on its lead clinical candidate EN‑374 for X‑linked...

Tel Aviv‑based Cassidy Bio closed an $8 million seed round to develop an AI platform that predicts optimal combinations of guide RNAs, editing enzymes and delivery modalities for therapeutic...

Profluent raised $106 million in a financing led by Altimeter Capital and Bezos Expeditions to expand its large‑scale AI models for protein design. The Emeryville company will use the funds to...

Researchers in David Liu’s lab at the Broad Institute described a prime‑editing strategy—termed PERT—that installs suppressor tRNAs via prime editing to rescue premature termination codons across...

Moderna announced a $1.5 billion financing to support its plans to expand an expected seasonal vaccine franchise and to fund investments in oncology and rare disease programs as it targets...

Function Health raised $298 million in a Series B round led by Redpoint Ventures, pushing its valuation to about $2.5 billion. The Austin‑based company offers consumer‑facing access to an expanded...

Abbott agreed to acquire Exact Sciences in an all-cash transaction that values the cancer‑testing company at roughly $21 billion (about $23 billion enterprise value), according to company filings...

Pfizer released full phase 3 data showing its mRNA seasonal influenza vaccine candidate delivered 34.5% greater efficacy than a standard control vaccine in the pivotal study. The readout expands...

The U.S. FDA granted approval to Bayer’s oral HER2‑directed kinase inhibitor Hyrnuo (sevabertinib) for adults with advanced HER2‑mutant non‑small‑cell lung cancer, and Thermo Fisher’s Ion Torrent...

Contineum Therapeutics reported that PIPE‑307, an oral M1 receptor antagonist developed with Janssen (J&J), failed to meet its primary efficacy endpoint in the Phase 2 VISTA trial for...

Moderna said it had secured $1.5 billion in financing to underpin operations as it pursues break‑even targets in 2028 and pivots investment toward an expanded seasonal vaccine franchise and...

Function Health closed a $298 million Series B led by Redpoint Ventures, lifting the lab‑testing startup’s valuation to about $2.5 billion. The company offers subscription access to a broad menu...